Grifols | GRFS - 流动负债

金融业

EUR

EUR 23.15B

现金及等价物

EUR 979.78M

EUR 1.51B

EUR 5.96B

EUR 2.37B

EUR 9.23B

股息收益率

EUR 1.88

EUR 320.55M

EUR 482.05M

EUR 23.83K

EPS每股收益

EUR 0.16

股本和储备

EUR 6.21B

EUR 766.49M

债务利息支出

EUR 156.07M

EUR 9.95B

EUR 1.92B

EUR 114.37M

EUR 1.99B

EUR 320.55M

普通股股本

EUR 680.58M

11.2

EUR 257.85M

EUR 2B

销售和管理费用

EUR 320.45M

EUR 3.56B

贸易债权人

EUR 987.75M

应收帐款人

EUR 1B

	流动负债	更改		日
Alaunos Therapeutics	USD 595K		218K	2026-03
Arca Biopharma	USD 16.63M		1.26M	2026-03
aTyr Pharma	USD 11.7M		101.49M	2026-03
Bio Path	USD 9.15M		468K	2026-03
Brainstorm Cell Therapeutics	USD 11.76M		757K	2026-03
Capricor Therapeutics	USD 33.64M		2.2M	2026-03
Cara Therapeutics	USD 11.04M		2K	2025-12
Esperion Therapeutics	USD 300.36M		451K	2026-03
GlaxoSmithKline	GBP 22.43B		1.04B	2026-03
Grifols	EUR 2.37B		156.97M	2025-12
Immunic	USD 38.36M		7.74M	2026-03
Minerva Neurosciences	USD 2.29M		381K	2025-12
Nektar Therapeutics	USD 53.54M		12.8M	2025-12
Sangamo BioSciences	USD 47.66M		1.9M	2025-06
TherapeuticsMD	USD 5.82M		655K	2024-06